Instillagel

Chlorhexidine Gluconate and Lidocaine Hydrochloride, the active ingredient in Instillagel, is an antiseptic and local anesthetic presented as a gel for urethral use. It provides antisepsis and analgesia during catheterisation and other urological procedures.

GNH USA supplies Instillagel as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Instillagel, containing an antiseptic and local anesthetic, is employed in the urological pathway for infection control and pain relief.

Urethral antisepsis prior to catheterisation: reduces bacterial colonisation and infection risk. Urethral analgesia during diagnostic procedures: provides local pain relief to improve patient comfort. Urethral analgesia during therapeutic procedures: enables tolerable insertion of instruments. Urethral preparation for endoscopic examinations: facilitates smooth instrument passage.

Instillagel may cause local and systemic adverse reactions.

Common Side Effects: - Mild urethral irritation. - Transient burning sensation. - Local redness. - Mild headache.

Serious or Rare Side Effects: - Allergic reaction (rash, angioedema). - Severe urethral inflammation. - Anaphylaxis.

Use Instillagel with attention to patient safety and handling.

Assess patient for known hypersensitivity: avoid use in individuals with documented allergy to chlorhexidine or lidocaine. Avoid use in active urethral infection unless indicated: consider alternative antiseptic. Do not exceed recommended volume: apply only as directed by healthcare professional. Monitor for systemic lidocaine effects: observe for signs of CNS toxicity in prolonged exposure. Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Instillagel can interact with other medicines; review patient medication list.

Major Interactions (Avoid): - Concurrent use with other local anesthetics: risk of cumulative lidocaine toxicity.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may potentiate lidocaine cardiac effects. - CYP450 inhibitors (e.g., amiodarone): may increase lidocaine plasma levels. - Anticoagulants: chlorhexidine may increase bleeding risk if mucosal integrity is compromised.